MedTrace Logo

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

NCT03159676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-02-25

No results posted yet for this study

Summary

Stereotactic ablative body radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), is a specialized form of radiotherapy used to treat prostate cancer with five treatments over two weeks, compared with a conventional eight-week or longer treatment course. The purpose of this trial is to investigate the effect that proton-based SABR has on quality-of-life in patients with localized prostate cancer. The evaluation and treatment will otherwise follow standard of care, and is not considered investigational.

Conditions

Interventions

RADIATION

Proton beam

Proton beam

Sponsors & Collaborators

Principal Investigators

  • Brad J. Stish, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-12
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159676 on ClinicalTrials.gov